Immunoglobulins market seen topping $34 billion by 2030

The global immunoglobulins market is projected to grow to $34.34 billion by 2030, driven by rising demand for immune disorder treatments and advances in plasma processing. North America and the U.S. are expected to remain the largest markets, while IGG keeps the biggest share of product sales.

Why it matters: - Immunoglobulins are a core treatment for immune-related and autoimmune conditions, so growth in this market tracks rising demand for therapies used across hospitals, infusion centers and specialty care. - The forecast points to continued expansion in plasma-derived medicines, a supply chain that depends on collection, fractionation and manufacturing capacity. - The market is also a meaningful slice of the broader blood products and pharmaceuticals industries, which makes its growth important for drugmakers, distributors and healthcare providers.

What happened: - The Business Research Company released its 2026 global market report on immunoglobulins on October 27, 2026. - The report projects the global immunoglobulins market will reach $34.34 billion by 2030. - The market is expected to grow at a compound annual growth rate of 11% through 2030. - North America is forecast to be the largest regional market at $13.1 billion in 2030. - The United States is projected to be the largest national market at $12.0 billion in 2030.

The details: - The report says immunoglobulins will make up about 72% of the blood products market in 2030, as that market reaches about $47 billion. - Within the broader pharmaceuticals industry, expected to reach $2,496 billion in 2030, immunoglobulins are projected to account for nearly 1%. - North America is expected to grow from $8.3 billion in 2025 to $13.1 billion in 2030, a 10% CAGR. - U.S. growth is projected to rise from $7.7 billion in 2025 to $12.0 billion in 2030, a 9% CAGR. - The IGG segment is expected to lead all product types, reaching about $26 billion in 2030 and representing 75% of the market. - IGG is projected to add $11 billion in value from 2025 to 2030. - IGA, IGM and IGE are each forecast to add about $1 billion over the same period, while IGD is expected to add about $0.3 billion. - The market is segmented by delivery mode into intravenous and subcutaneous administration. - Key applications include hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis and idiopathic thrombocytopenic purpura. - CSL Behring LLC held an 8% share of global immunoglobulins sales in 2025, making it the leading company in the sector. - The report names other major companies including Takeda Pharmaceutical Company Limited, Grifols S.A., Octapharma AG, Kedrion S.p.A., Shanghai RAAS Blood Products Co., Ltd., China Biologic Products Holdings Inc., Biotest AG, Bio Products Laboratory Ltd., LFB S.A., ADMA Biologics Inc. and Baxter International Inc. - The top 10 players accounted for about 30% of total market revenue in 2025, showing a moderately concentrated market. - Barriers to entry include strict regulatory approvals, complex plasma collection and fractionation, quality and safety standards, and cold chain logistics.

Between the lines: - The market’s growth is being driven by the rising prevalence of autoimmune and immunodeficiency disorders, including CIDP, primary immunodeficiency diseases, Guillain-Barré syndrome and lupus. - Better awareness, earlier diagnosis and wider access to specialty care are expanding use of immunoglobulin replacement and immune-modulating treatments. - Advances in plasma fractionation, purification, viral inactivation and automation are improving yield, safety and production scale. - The report also points to greater adoption of subcutaneous delivery, specialty pharmacy distribution and product innovation as competitive advantages. - GC Biopharma launched ALYGLO 10% Liquid IVIG in the U.S. in September 2024 for adult primary humoral immunodeficiency, highlighting ongoing product development in the category. - Companies are also leaning on manufacturing expansion, AI-enabled compliance and stronger plasma networks to defend market share.

What's next: - The report expects continued expansion across all immunoglobulin types as therapies move into more clinical settings and indications. - Greater capacity in plasma collection and fractionation is likely to remain a priority as demand rises. - Strategic partnerships, geographic diversification and supply chain investment are expected to shape competition through 2030. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards and updated graphics.